Well, again, there were plenty of tools, including the corrective action plans we have talked about and the enhanced oversight plans, short of even terminating.

Thank you, Senator Lankford. And, again, Dr. Harrington, thanks for your help on this, and your expertise has been helpful to us as we have gone through this report and tried to figure out how this could have happened.

I think it also was to get enrollment numbers up under Obamacare, which was part of the desire by the White House at the time, and continues to be.

And, again, just to be clear, as compared to some of the testimony we heard earlier, there was information.

This was the fault of HHS, the way the program was structured.

Certainly 300 percent was not enough.

Let me give you a few highlights.

I hope this hearing gets a lot of attention, and I hope your testimony gets a lot of attention.

Let me tell you what the New York CO-OP situation is, because you question our numbers or you have not looked at the numbers yourselves. This is how we got into that mess. It vastly overshot its enrollment targets while underpricing its…

I just think it is totally inappropriate for you all to say, as Mr. Slavitt just did, they did the best job they could with the information they had, and that somehow, this is just a problem with startups.

Deloitte will not provide an opinion regarding the reasonableness of the proposed changes to each CO-OP's business plan.